Product Description.:
BEACH, 11 25
tablet , film-coated , white , scored , oblong oblong
Each tablet contains 852 mg dibasic sodium phosphate anhydrous, 155 mg monobasic potassium phosphate, and 130 mg monobasic sodium phosphate monohydrate. Each tablet yields approximately 250 mg of phosphorus, 298 mg of sodium (13.0 mEq) and 45 mg of potassium (1.1 mEq).
INDICATIONS
K-PHOS? NEUTRAL increases urinary phosphate and pyrophosphate. As a phosphorus supplement, each tablet supplies 25% of the U.S. Recommended Daily Allowance (U.S. RDA) of phosphorus for adults and children over 4 years of age.
DOSAGE AND ADMINISTRATION
K-PHOS? NEUTRAL tablets should be taken with a full glass of water, with meals and at bedtime. Adults: One or two tablets four times daily Pediatric Patients over 4 years of age: One tablet four times daily. For Pediatric Patients under 4 years of age, use only as directed by a physician.
HOW SUPPLIED
White, film-coated, capsule-shaped tablet with the name BEACH and number 1125 imprinted on each tablet. Bottles of 100 (NDC 0486-1125-01) and 500 (NDC 0486-1125-05) tablets.
SIDE EFFECTS
Gastrointestinal upset (diarrhea, nausea, stomach pain, and vomiting) may occur with phosphate therapy. Also, bone and joint pain (possible phosphate-induced osteomalacia) could occur. The following adverse effects may be observed (primarily from sodium or potassium): headaches dizziness mental confusion seizures weakness or heaviness of legs unusual tiredness or weakness muscle cramps numbness, tingling, pain, or weakness of hands or feet numbness or tingling around lips fast or irregular heartbeat shortness of breath or troubled breathing swelling of feet or lower legs unusual weight gain low urine output unusual thirst.
DRUG INTERACTIONS
The use of antacids containing magnesium, aluminum, or calcium in conjunction with phosphate preparations may bind the phosphate and prevent its absorption. Concurrent use of antihypertensives, especially diazoxide, guanethidine, hydralazine, methyldopa, or rauwolfia alkaloid or corticosteroids, especially mineralocorticoids or corticotropin, with sodium phosphate may result in hypernatremia. Calcium-containing preparations and/or Vitamin D may antagonize the effects of phosphates in the treatment of hypercalcemia. Potassium-containing medications or potassium-sparing diuretics may cause hyperkalemia. Patients should have serum potassium level determinations at periodic intervals.